RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Cequent, which was acquired by Marina Biotech in 2010, developed new, clinically compatible therapies based on RNA interference (RNAi) therapies. The company focused its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.
Cequent Pharmaceuticals
Cambridge, MA
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.